Compare Dow Inc (DOW) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Revvity Inc — how do they compare? Dow Inc trades at $28.42 (market cap $20.65B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Dow Inc is the larger of the two by market cap, and Dow Inc pays the higher dividend (4.9%). Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and Revvity Inc for 12 Days on average.
| DOW | RVTY | |
|---|---|---|
Market Cap | $20.65B | $16.98B |
Volume | 14,126,943 | 1,456,900 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $157.36 |
52-Week Low | $20.65 | $82.26 |
Typical Hold Time | 82 Days | 12 Days |
Enterprise Value | $36.34B | $19.30B |
Dividend Yield | 4.9% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $28.59, up 2.95% today, near the analyst low target of $28.00. The stock shows a bullish technical signal despite mixed indicators, with recent earnings beats in Q4 2025 through Q2 2026. However, fundamentals are weak, with a negative net income margin of -3.13% in 2025 and declining revenue from $56.9B in 2022 to $40.0B in 2025. Cash flow trends improved in 2025, but debt-to-asset ratios have risen to 29.87%.
The outlook is cautious; while analyst consensus is a buy with a $34.22 target, high valuation (P/E 75.93) and profitability challenges pose risks. Opportunities include dividend stability and potential margin recovery, but investors face headwinds from cyclical demand and competitive pressures in the chemicals sector.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
